Recently, the China Bio-Manufacturing Industry Development Conference, themed ‘Synthetic Biology: Boundless Vitality’, was held in Shijiazhuang, Hebei Province. The event unveiled the ‘2023 List of Rising Stars in Bio-Manufacturing’, aiming to establish a professional exchange and collaboration platform within China's bio-manufacturing sector and propel its vigorous development. The conference brought together academicians, experts, leading enterprises, and representatives from investment institutions for in-depth discussions, collectively striving to foster an open ecosystem featuring a virtuous cycle of ‘technology-industry-finance’.

At this prestigious event, Synaura Biotech's inclusion on the list stood out as a highlight. This recognition not only signifies high praise for its R&D innovations in the food biomanufacturing sector but also fully affirms its contributions to advancing the industry's development.

Synaura Biotech Honoured on the 2023 List of Rising Stars in the Biomanufacturing Sector

He Yaqiong, Director-General of the Department of Consumer Goods Industry at the Ministry of Industry and Information Technology, stated that the biotechnology sector represents one of the most promising strategic emerging industries for the future. Advancements in biomanufacturing hold the potential to reshape industrial ecosystems and future development paradigms, constituting an essential requirement for advancing new industrialisation. The China Bio-Manufacturing Industry Development Conference, renowned for its professionalism and authority, is hailed as the ‘barometer’ of China's bio-economy sector. The companies featured on this list of emerging enterprises in bio-manufacturing not only represent the vanguard of China's innovation journey in bio-manufacturing, but their pioneering ventures also signal potential future trajectories for the industry.

Five Key Advantages of Synaura HMO

Synaura Biotech employs advanced microbial fermentation technology to produce HMO, meticulously refining its products. Through continuous process optimisation, the resulting HMO exhibits uniform particle size, high purity, and no residual acetic acid odour – perfectly embodying the fusion of craftsmanship and technological innovation. Extensive customer validation has demonstrated that Synaura Biotech's HMOs have gained widespread market recognition for their exceptional quality, ease of application, and adaptability to diverse production methods including dry and wet processes. Simultaneously, this accolade serves as both an incentive and a spur for the future—driving Synaura Biotech to deepen its innovative researchbio-active ingredients like human milk oligosaccharides, continuously enhance its scientific and production capabilities in the field of biosynthesis, and fulfil its mission of independent innovation. This endeavour will propel China towards becoming a flagship leader in the Fourth Industrial Revolution.

The future is here, and China's era of independent innovation has arrived!